Company intelligence / Profile preview

Amber Bio

San Francisco, California, United Statesamber.bio ↗

Ownership: Private
Employees: ~7
Development stage: Preclinical

Overview

Amber Bio is developing a first-of-its-kind gene editing platform capable of making large, multi-kilobase edits at the RNA level. This approach aims to enable single-drug solutions for diseases caused by thousands of different mutations, addressing previously undruggable patient populations. The company remains in pre-clinical development; no clinical results have been reported yet.

Therapeutic areas: Rare Diseases
Modalities: RNA-based gene editing (multi-kilobase RNA writing)CRISPR-based technologies
Industry: Biotech

Partnerships

Investors include Playground Global, Andreessen Horowitz Bio + Health, Eli Lilly, Retinal Degeneration Fund (RD Fund), Hummingbird Ventures, Pillar VC

Beyond the preview

Go deeper on Amber Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amber Bio.

Explore the full profile